Ghanem A, Borghol A, Munairdjy Debeh F, Paul S, Alkhatib B, Harris P
Kidney Int Rep. 2024; 9(10):2860-2882.
PMID: 39435347
PMC: 11492289.
DOI: 10.1016/j.ekir.2024.07.012.
De Rosa L, Catania M, Tunesi F, Vespa M, Bucci R, Kola K
Case Rep Nephrol Dial. 2024; 14(1):116-121.
PMID: 39015122
PMC: 11250061.
DOI: 10.1159/000538951.
Bais T, Geertsema P, Knol M, van Gastel M, de Haas R, Meijer E
Clin J Am Soc Nephrol. 2024; 19(5):591-601.
PMID: 38407866
PMC: 11108249.
DOI: 10.2215/CJN.0000000000000427.
Wigerinck S, Gregory A, Smith B, Iliuta I, Hanna C, Chedid M
Clin Kidney J. 2023; 16(10):1691-1700.
PMID: 37779848
PMC: 10539251.
DOI: 10.1093/ckj/sfad114.
Rosenberg M, Yaneff A, Ferradas G, Villafane Tapia M, Davio C, Goette N
Life (Basel). 2023; 13(9).
PMID: 37763221
PMC: 10532713.
DOI: 10.3390/life13091817.
Elevated checkpoint inhibitor expression and Treg cell number in autosomal dominant polycystic kidney disease and their correlation with disease parameters and hypertension.
Sahin A, Kocyigit I, Aslan K, Eroglu E, Demiray A, Eken A
Clin Exp Med. 2023; 23(7):3631-3640.
PMID: 36869968
DOI: 10.1007/s10238-023-01031-2.
Glomerular hyperfiltration.
Cortinovis M, Perico N, Ruggenenti P, Remuzzi A, Remuzzi G
Nat Rev Nephrol. 2022; 18(7):435-451.
PMID: 35365815
DOI: 10.1038/s41581-022-00559-y.
The correlation between kidney volume and measured glomerular filtration rate in an Asian ADPKD population: a prospective cohort study.
Phakdeekitcharoen B, Treesinchai W, Wibulpolprasert P, Boongird S, Klytrayong P
BMC Nephrol. 2021; 22(1):178.
PMID: 33992075
PMC: 8126117.
DOI: 10.1186/s12882-021-02392-0.
Prevalence, risk factors and disease knowledge of polycystic kidney disease in Pakistan.
Zahid R, Akram M, Rafique E
Int J Immunopathol Pharmacol. 2020; 34:2058738420966083.
PMID: 33125856
PMC: 7607775.
DOI: 10.1177/2058738420966083.
Quest for the Cure: Testing the Old and New to Prevent Progression of Autosomal Dominant Polycystic Kidney Disease.
Brosnahan G
Kidney Med. 2020; 1(6):329-331.
PMID: 33015606
PMC: 7525136.
DOI: 10.1016/j.xkme.2019.10.004.
Targeting and therapeutic peptide-based strategies for polycystic kidney disease.
Wang J, Tripathy N, Chung E
Adv Drug Deliv Rev. 2020; 161-162:176-189.
PMID: 32866560
PMC: 7736157.
DOI: 10.1016/j.addr.2020.08.011.
The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD.
Lavu S, Vaughan L, Senum S, Kline T, Chapman A, Perrone R
JCI Insight. 2020; 5(15).
PMID: 32634120
PMC: 7455088.
DOI: 10.1172/jci.insight.138724.
Renal Volume in ADPKD Patient Evaluation.
Galliani M, Vitaliano E, Chicca S, Calvaruso L, Di Lullo L, Iorio F
Int J Nephrol. 2020; 2020:9286728.
PMID: 32158561
PMC: 7060877.
DOI: 10.1155/2020/9286728.
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease.
Yu A, Shen C, Landsittel D, Grantham J, Cook L, Torres V
Kidney Int. 2019; 95(5):1253-1261.
PMID: 30922668
PMC: 6478515.
DOI: 10.1016/j.kint.2018.12.023.
Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.
Brosnahan G, Abebe K, Moore C, Rahbari-Oskoui F, Bae K, Grantham J
Am J Kidney Dis. 2018; 71(5):666-676.
PMID: 29306517
PMC: 5916329.
DOI: 10.1053/j.ajkd.2017.10.023.
Grayscale ultrasound characteristics of autosomal dominant polycystic kidney disease severity - an adult and pediatric cohort study.
Strzelczyk M, Podgorski M, Afshari S, Tkaczyk M, Pawlak-Bratkowska M, Grzelak P
J Ultrason. 2017; 17(69):85-90.
PMID: 28856014
PMC: 5516076.
DOI: 10.15557/JoU.2017.0011.
The importance of total kidney volume in evaluating progression of polycystic kidney disease.
Grantham J, Torres V
Nat Rev Nephrol. 2016; 12(11):667-677.
PMID: 27694979
PMC: 5497709.
DOI: 10.1038/nrneph.2016.135.
Pravastatin Therapy and Biomarker Changes in Children and Young Adults with Autosomal Dominant Polycystic Kidney Disease.
Klawitter J, McFann K, Pennington A, Wang W, Klawitter J, Christians U
Clin J Am Soc Nephrol. 2015; 10(9):1534-41.
PMID: 26224879
PMC: 4559520.
DOI: 10.2215/CJN.11331114.
A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease.
Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham J, Torres V
Kidney Int. 2015; 88(1):146-51.
PMID: 25830764
PMC: 4490113.
DOI: 10.1038/ki.2015.71.
Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients.
Zittema D, van den Berg E, Meijer E, Boertien W, Muller Kobold A, Franssen C
Clin J Am Soc Nephrol. 2014; 9(9):1553-62.
PMID: 24993447
PMC: 4152815.
DOI: 10.2215/CJN.08690813.